Alfentanil: Simultaneous Testing Pilot

Completed · Not applicable

Conditions studied: Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A

In brief

To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity.

Key facts

Study ID

NCT01008059

Run by

Washington University School of Medicine

People needed

6

Starts

2009-10-01

Expected to finish

2016-09-01

Last updated by the study team

2019-05-17

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or non-pregnant female, 18-40 yr. old
• Good general health with no remarkable medical conditions such as liver, kidney, heart, or lung failure
• BMI between 20-33
• Provide informed consent

You may not qualify if…

• Known history of liver or kidney disease
• Use of prescription or non prescription medications, herbals or foods known to be metabolized by or affect CYP3A (including oral birth control medications)
• Females who are pregnant or nursing
• Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)
• Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential).
• History of bradycardia
• Respiratory rate <10
• History of significant pulmonary disease
• History of pre-existing medical condition predisposing to respiratory depression
• Systolic blood pressure <100 mgHg and diastolic blood pressure <70mmHg

Where it is running

• Washington University/Barnes Jewish Hospital — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.